NEWS RELEASE RECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES FIRST HALF 2026 NET REVENUE +6.6%, EBITDA(1) +8.8%, ADJUSTED NET INCOME(2) +6.7% • • • • • • • Consolidated net revenue of € 1,410.8 million in the first half of 2026, +6.6% or +9.1% on…
NEWS RELEASE
RECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES
FIRST HALF 2026 NET REVENUE +6.6%, EBITDA(1) +8.8%,
ADJUSTED NET INCOME(2) +6.7%
•
•
•
•
•
•
•
Consolidated net revenue of € 1,410.8 million in the first half of 2026, +6.6% or +9.1% on a like-forlike basis(3) at constant exchange rates (CER); adverse FX impact of € 34.5 million (-2.6%)
EBITDA(1) of € 540.2 million, +8.8%, margin on net revenue of 38.3%
Adjusted net income(2) of € 349.9 million, +6.7%, margin on net revenue of 24.8%
Net income of € 269.7 million, +24.8%
Free cash flow(4) of € 299.4 million, +€ 42.6 million vs prior year
Net debt(5) at € 1,917.1 million, below 1.9x EBITDA
FY 2026 financial targets confirmed
Milan, 28th July 2026 – The Board of Directors of Recordati S.p.A. approved the interim financial
statements as of June 30, 2026, pursuant to Art. 154-ter of Italian Legislative Decree 58/1998 and
subsequent amendments, prepared in accordance with said Decree and the CONSOB Issuers Regulation.
The statements were prepared in accordance with International Accounting Standard (IAS) 34
requirements for interim reporting, based on the assessment, measurement and recognition criteria set
by the IFRSs. The interim financial statements on June 30, 2026 – as well as the Independent Auditors’
report on such statements - will be available within the legal deadline at the company’s offices and on
the company’s website (www.recordati.com) and can also be viewed on the authorized storage system
1Info (www.1Info.it).
Rob Koremans, Chief Executive Officer of Recordati, commented: “Our strong first half performance
reflects the strength of our diversified portfolio and the disciplined execution of our strategy. Rare
Diseases remains the key growth driver, with Isturisa® delivering another excellent quarter driven by
expanded physician adoption, increased patient demand and improved commercial execution. As
planned, we are stepping up our investments to support the future growth of our Rare Diseases portfolio
with the U.S. expansion of Isturisa® and other lifecycle management initiatives including sutimlimab for
ITP and Qarziba® in the U.S. We further strengthened our pipeline through our licensing agreement with
Ionis, adding a late-stage development program for Alexander disease that has the potential to address
a devastating disease with no approved treatment options. We remain well positioned to build on this
momentum and continue creating long-term value.”
H1 2026 Financial highlights
•
Consolidated net revenue for the first half of 2026 was € 1,410.8 million, up 6.6% or 9.1% on a
like-for-like(3) basis at CER (+7.8% excluding Türkiye) versus the first half of 2025. This was driven,
in particular, by the strong momentum from the Rare Diseases business. The adverse FX impact for
the first half of 2026 was € 34.5 million (-2.6%), mainly driven by the U.S. dollar and Turkish lira
devaluation.
RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.
Registered Office
Via Matteo Civitali, 1
20148 Milano, Italy
Tel. +39 02 487871
Fax +39 02 40073747
www.recordati.com
Share Capital € 26.140.644,50 fully paid-up
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150
Tax Code/VAT No. 00748210150
Milano R.E.A. No. 401832
Company subject to the Management and Coordination Activity of Rossini Luxembourg S.àr.l
o
Rare Diseases revenue was € 603.9 million for the first half of 2026, up 17.1%, or 22.0%
on a like-for-like(3) basis at CER as compared to the first half of 2025, driven by strong
volume growth across the Endocrinology and Hema-Oncology franchises. The
Endocrinology franchise achieved net revenue of € 247.6 million, an increase of 39.0%,
reflecting continued growth of Isturisa® (€ 178.8 million, +58.0%), driven by strong new
patient uptake in the U.S. and growth of Signifor® (€ 68.8 million, +5.8%). The HemaOncology franchise achieved net revenue of € 230.4 million, growing by 14.8%,
reflecting the strong momentum of Enjaymo® across geographies (€ 91.0 million,
+31.1%), as well as growth of Qarziba® (€ 83.7 million, +6.5%) and Sylvant® (€ 48.1
million, +6.4%). The Metabolic franchise achieved net revenue of € 125.9 million, a
decrease of 8.0%, reflecting phasing of Carbaglu® across geographies and slightly lower
demand of Panhematin® in the U.S. against a strong performance in the first half of
2025.
o
Specialty & Primary Care revenue was € 773.5 million for the first half of 2026, down
0.1% or up 0.6% on a like-for-like(3) basis at CER as compared to the first half of 2025(6),
reflecting continued in-market growth of the promoted portfolio (+7.0%(7)) and some
expected one-off headwinds. In particular, the Cardiovascular franchise achieved net
revenue of € 213.3 million, a decrease of 1.6%, mainly reflecting the loss of the Cardicor®
license and lower sales of mature products due to phasing, mostly offset by the growing
contribution of Vazkepa®. The Urology franchise achieved net revenue of € 209.3
million, an increase of 1.0%, driven by the strong performance of Eligard® benefiting
from a competitor stock-out in Türkiye as well as by local products, mostly offset by the
one-off Tergynan® re-launch in Russia in 2025. The Gastrointestinal franchise achieved
net revenue of € 135.8 million, an increase of 3.9%, mainly driven by Procto-Glyvenol®.
The Cough & Cold franchise achieved net revenue of € 53.6 million, a decrease of 9.7%
due to a weaker season in key markets.
•
EBITDA(1) was € 540.2 million for the first half of 2026, up 8.8% compared to the first half of 2025,
with margin of 38.3% of net revenue. Strong revenue performance and the positive mix effect at
the gross profit level was partially offset by a higher level of investments to support the U.S.
expansion, primarily for Isturisa®, the continued development of Enjaymo®, ongoing geographic
expansion in Rare Diseases as well as the launch of Vazkepa ® in Specialty & Primary Care.
•
Adjusted operating income(8) was € 434.8 million in the first half of 2026, an increase of 10.2%
versus the first half of 2025. This represents 30.8% of net revenue, compared with 29.8% in the prior
year, supported by strong operating performance. Operating income was € 419.2 million in the
first half of 2026, up 26.6% over the first half of 2025, when non-cash charges of € 46.9 were posted,
mainly due to the fair value revaluation of the inventory acquired as part of the acquisition of the
Enjaymo® rights. Non-recurring costs were €15.6 million, compared with €16.8 million in the first
half of 2025, mainly reflecting the acceleration of the LTI Performance Share Plan triggered by the
potential delisting of Recordati.
•
Financial expenses were € 57.3 million in the first half of 2026, up by € 10.6 million compared to
the same period of the previous year, mainly due to net exchange rate losses of € 4.2 million as
compared to exchange rate gains of € 7.5 million in the first half of 2025, with the variance mainly
driven by U.S. dollar exchange rate movements. The impact of hyperinflation was negative € 3.0
million compared to € 2.5 million in the first half of 2025.
2
•
Adjusted net income(2) was € 349.9 million, 24.8% of net revenue, up by 6.7% compared to the
same period of 2025, benefitting from higher adjusted operating income, partly offset by higher
financial expenses and tax rate. Net income was € 269.7 million, 19.1% of net revenue, an increase
of 24.8% versus the prior year, reflecting higher operating income, despite the higher financial
expenses and income tax rate versus the first half of 2025.
•
Free cash flow(4) was € 299.4 million for the first half of 2026, an increase of € 42.6 million versus
the first half of 2025, driven primarily by higher EBITDA.
•
Net debt(5) as of June 30, 2026 was € 1,917.1 million, or leverage below 1.9x EBITDA, compared to
net debt of € 2,037.3 million on December 31, 2025.
•
Shareholders’ equity was € 2,130.6 million.
Pipeline Development
The osilodrostat (Isturisa®) Phase IV study in patients with hypertension caused by hypercortisolemia
due to Cushing’s syndrome is expected to begin enrollment in August 2026.
The Phase 2 trial evaluating pasireotide for the treatment of post-bariatric hypoglycemia met its primary
endpoint with a dose-dependent and significant increase in glucose levels during a standardized meal
test (p<0.02)(9). The Phase 3 development plan is expected to be finalized by the end of 2026.
On the basis of encouraging FDA feedback as well as early clinical evidence showing that sutimlimab, by
targeting the classical complement pathway, can lead to a rapid and sustained platelet response in
patients with immune thrombocytopenia (ITP) refractory to multiple lines of treatment, Recordati
expects to advance sutimlimab into a pivotal registrational Phase 3 trial for the treatment of chronic ITP
at the beginning of 2027.
The other lifecycle management programs are progressing in line with plans.
Corporate Development
On January 29, 2026, Recordati announced a collaboration and license agreement with Moderna to
develop and commercialize worldwide mRNA-3927, an investigational product for the treatment of
propionic acidemia (PA). Under the terms of the agreement, Moderna will continue to lead the
development of mRNA-3927, in collaboration with Recordati, and if approved, Recordati will lead global
commercialization. mRNA-3927 is a post proof-of-concept, investigational product aimed to restore
propionyl-CoA carboxylase (PCC) enzyme activity in patients with propionic acidemia. If approved, this
could be the first disease-modifying treatment option on the market for this severe disease. mRNA-3927
is currently being evaluated in a potential registrational clinical study. The target patient enrollment has
been reached, with a data readout expected by the end of 2026.
On June 25, 2026, Recordati announced a license agreement with Ionis Pharmaceuticals, Inc. for exclusive
development and commercialization rights to zilganersen, an investigational RNA-targeted medicine for
the treatment of Alexander disease (AxD), in all countries outside the U.S. Recordati will be responsible
for regulatory filings and commercialization outside the U.S., including country-specific support for early
access pathways based on local regulations and access dynamics. Ionis will maintain sole commercial
responsibility for zilganersen in the U.S. and will continue to lead development globally. Alexander
disease is a rare, progressive and often fatal neurological disorder caused by mutations in the GFAP
3
gene. The disease affects astrocytes, critical support cells in the brain, leading to progressive loss of
neurological function, including mobility, independence, swallowing and breathing. There are currently
no approved disease-modifying therapies for AxD.
Business outlook
The Group confirms its financial targets for full year 2026 as follows:
•
•
•
Net revenue between € 2,730 and € 2,800 million with FX headwind of ~-3.5%
EBITDA(1) between € 995 and € 1,030 million; margin of +/- 36.5% with FX headwind of ~-4.0%
Adjusted net income(2) between € 655 and € 685 million; margin of +/- 24.0%
The full year 2027 targets(10) remain unchanged, with strong organic growth complemented by bolt-on
business development and M&A.
(1) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of
property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from
the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS.
(2) Net income excluding amortization and write-downs of intangible assets (except software) and goodwill, nonrecurring items, non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin
of acquired inventory as foreseen by IFRS 3, monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.
(3) Pro-forma growth calculated excluding revenue of Vazkepa® and Cardicor® for H1 2026 and H1 2025 (Specialty
& Primary Care) and Inrebic® for H1 2026 (Rare Diseases).
(4) Total cash flow excluding financing items, milestones, dividends, purchases of treasury shares net of proceeds from
exercise of stock options.
(5) Cash and cash equivalents, less bank debts and loans, which include the measurement at fair value of hedging
derivatives.
(6) The 2025 figures have been restated to reflect the reclassification of certain brands from Other Therapeutic areas to
Cardiovascular and Gastrointestinal areas in 2026. The amount of reclassification for H1 2025 is as follows: €3.4 million
from Other Therapeutic areas to Cardiovascular area and €6.9 million from Other Therapeutic areas to Gastrointestinal
area.
(7) IQVIA May-YTD.
(8) Net income before income taxes, financial income and expenses and non-recurring items, non-cash charges arising
from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS
3.
(9) p=0.0106 (50 µg s.c. pasireotide vs placebo); p=0.0010 (100 µg s.c. pasireotide vs. placebo); p< 0.0001 (200 µg s.c.
pasireotide vs placebo).
(10) FY 2027 targets: Net Revenue €3,000 - €3,200 million, EBITDA €1,140 - €1,225 million, Adjusted Net Income €770€820 million, excluding potential impact from tariffs and/or most favored nation pricing policies in the U.S.
Conference Call
Recordati will host a conference call on July 29th, at 2:00 p.m. CEST (1:00 p.m. BST) to present the
results for the first half of 2026. Please find the pre-registration link here with all the dial-in details and
a calendar invitation to follow.
Alternatively, if not pre-registered, the dial-in numbers for the conference call are:
Italy + 39 02 802 09 11, toll free 800 231 525
UK + 44 1 212818004, toll free (44) 0 800 0156371
USA +1 718 7058796, toll free (1) 1 855 2656958
France +33 1 70918704
Germany +49 6917415712
4
Participants are invited to dial in 10 minutes before the start of the conference call. If operator
assistance is required to connect, please dial *0.
The slides that will be referenced during the call will be available at www.recordati.com under
Investors/Company Presentations.
Recordati is an international pharmaceutical Group listed on the Italian Stock Exchange (XMIL: REC), with roots
dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide
treatments across specialty and primary care and rare diseases. Our fully integrated operations span clinical
development, manufacturing of active ingredients and finished products, commercialization and licensing. We
operate in approximately 150 countries across EMEA, the Americas and APAC, with around 4,700 employees. We
believe that health is a fundamental right, not a privilege. Today, our purpose “Unlocking the full potential of life”
aims to empower individuals to live life to the fullest, from common conditions to the rarest.
Investor Relations
Eugenia Litz
[email protected]
Gianluca Saletta
[email protected]
Media Relations
Laura Conti
[email protected]
Rebecca Kerr
[email protected]
This document contains forward-looking statements relating to future events and future operating, economic and
financial results of the Recordati group. By their nature, forward-looking statements involve risk and uncertainty
because they depend on the occurrence of future events and circumstances. Actual results may therefore differ
materially from those forecast for a variety of reasons, most of which are beyond the Recordati group’s control. The
information on the pharmaceutical specialties and other products of the Recordati group contained in this document
is intended solely as information on the activities of the Recordati Group, and, as such, it is not intended as a medical
scientific indication or recommendation, or as advertising.
5
MAIN PRODUCTS NET REVENUE
(€ thousands)
First half 2026
First half 2025
773,514
774,441
Change
%
(0.1)
99,736
106,555
(6.4)
69,088
63,116
9.5
50,436
52,717
(4.3)
50,055
57,407
(12.8)
43,337
44,133
(1.8)
Livazo (pitavastatin)
36,200
28,181
28.5
Vazkepa® (ethyl-icosapent)
14,039
n.a.
Rare Diseases
603,925
515,739
17.1
®
Isturisa (osilodrostat)
178,822
113,161
58.0
Signifor® / Signifor LAR (pasireotide)
Specialty & Primary Care
Zanidip® (lercanidipine) and Zanipress®
(lercanidipine+enalapril)1
Eligard® (leuprorelin acetate)
Avodart® (dutasteride) and
Combodart®/Duodart®
(dutasteride/tamsulosin)2
Seloken®/Seloken® ZOK/Logimax®
(metoprolol/metoprolol+felodipine)
Urorec® (silodosin)
®
68,820
65,061
5.8
®
90,983
69,402
31.1
®
83,679
78,569
6.5
®
48,134
45,232
6.4
Enjaymo (sutimlimab)
Qarziba (dinutuximab beta)
Sylvant (siltuximab)
(1) of which Zanidip® € 84.1 million in H1 2026 and € 90.9 million in H1 2025
(2) Trademarks are owned by or licensed to the GSK group of companies
6
RECORDATI GROUP
Summary of the consolidated results, prepared in accordance with International Financial Reporting Standards (IFRS)
(€ thousands)
INCOME STATEMENT
First half 2026
First half 2025
Change
%
NET REVENUE
1,410,779
1,323,842
6.6
Cost of sales
(401,979)
(441,220)
(8.9)
GROSS PROFIT
1,008,800
882,622
14.3
Selling expenses
(302,514)
(284,729)
6.2
Research and development expenses
(179,051)
(167,118)
7.1
General and administrative expenses
(91,828)
(83,643)
9.8
Other income/(expenses), net
(16,204)
(16,101)
0.6
OPERATING INCOME
419,203
331,031
26.6
Financial income/(expenses), net
(57,296)
(46,680)
22.7
PRE-TAX INCOME
361,907
284,351
27.3
Income taxes
(92,233)
(68,230)
35.2
269,674
216,121
24.8
1,008,800
929,541
8.5
434,808
394,703
10.2
349,852
327,763
6.7
540,196
496,345
8.8
269,674
216,121
24.8
0
0
n.s.
1.323
1.048
26.2
1.292
1.033
25.1
NET INCOME
Adjusted gross profit
(1)
Adjusted operating income
Adjusted net income
(2)
(3)
(4)
EBITDA
Net income attributable to:
Equity holders of the Parent
Non-controlling interests
EARNINGS PER SHARE (euro)
Basic(5)
(6)
Diluted
(1) Gross profit adjusted from impact of non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired inventory
as foreseen by IFRS 3.
(2) Net income before income taxes, financial income and expenses, non-recurring items and non-cash charges arising from the allocation of the purchase price
of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3.
(3) Net income excluding amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from
the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3, monetary net gains/losses from hyperinflation
(IAS 29), net of tax effects.
(4) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible
assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired
inventory as foreseen by IFRS 3.
(5) Earnings per share (EPS) are based on average shares outstanding during the respective period, 203.782.149 in 2026 and 206.134.192 in 2025. These amounts
are calculated deducting treasury shares in the portfolio, the average of which was 5.343.007 shares in 2026 and 2.990.964 shares in 2025.
(6) Diluted earnings per share is calculated considering rights granted to beneficiaries of stock options and performance shares plans.
COMPOSITION OF NET REVENUE
Change
%
First half 2026
First half 2025
Italy
1,410,779
169,565
1,323,842
182,430
(7.1)
International
1,241,214
1,141,412
8.7
Total revenue
Pending completion of independent audit
7
6.6
RECORDATI GROUP
(€ thousands)
Reconciliation of Net income to EBITDA(1)
Net income
Income taxes
Financial income/(expenses), net
Non-recurring expenses
Non-cash charges from PPA inventory uplift
Adjusted operating income(2)
Depreciation, amortization and write-downs
First half
2026
269,674
92,233
57,296
15,605
0
434,808
105,388
First half
2025
216,121
68,230
46,680
16,753
46,919
394,703
101,642
EBITDA(1)
540,196
496,345
Reconciliation of Net income to Adjusted Net income(3)
Net income
Amortization and write-downs of intangible assets
(excluding software)
Tax effect
Non-recurring operating expenses
Tax effect
Non-cash charges from PPA inventory uplift
Tax effect
Monetary net (gain)/losses from hyperinflation (IAS29)
Tax effect
Adjusted net income(3)
(1)
First half
2026
269,674
First half
2025
216,121
83,178
81,779
(19,227)
15,605
(2,350)
0
0
2,972
0
349,852
(19,329)
16,753
(4,662)
46,919
(11,730)
2,516
(604)
327,763
Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible
assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of acquisitions to the gross margin of acquired
inventory as foreseen by IFRS 3.
(2) Net income before income taxes, financial income and expenses, non-recurring items and non-cash charges arising from the allocation of the purchase price of
acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3.
(3)
Net income excluding amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from
the allocation of the purchase price of acquisitions to the gross margin of acquired inventory as foreseen by IFRS 3, monetary net gains/losses from hyperinflation
(IAS 29), net of tax effects.
Pending completion of independent audit
8
RECORDATI GROUP
Summary of the consolidated results, prepared in accordance with International Financial Reporting Standards (IFRS)
(€ thousands)
ASSETS
Property, plant and equipment
30.06.2026
230,743
31.12.2025
222,324
Intangible assets
2,400,054
2,393,448
Goodwill
Other equity investments and securities
Other non-current assets
Deferred tax assets
TOTAL NON-CURRRENT ASSETS
806,380
17,870
11,122
144,168
3,610,337
795,680
16,244
10,259
136,415
3,574,370
Inventories
Trade receivables
Other receivables
Other current assets
Derivative instruments measured at fair value
Cash and cash equivalents
TOTAL CURRENT ASSETS
550,339
651,841
126,865
30,042
7,496
391,383
1,757,966
539,804
570,154
106,458
24,591
8,074
428,824
1,677,905
TOTAL ASSETS
5,368,303
5,252,275
Pending completion of independent audit
9
RECORDATI GROUP
Summary of the consolidated results, prepared in accordance with International Financial Reporting Standards (IFRS)
(€ thousands)
EQUITY AND LIABILITIES
30.06.2026
31.12.2025
26,141
83,719
(214,180)
2,768
(338,010)
94,972
2,205,545
269,674
0
26,141
83,719
(239,379)
(17)
(348,362)
73,822
2,009,007
443,624
(128,783)
2,130,629
1,919,772
0
0
2,130,629
1,919,772
Loans - due after one year
Provisions for employee benefits
Deferred tax liabilities
TOTAL NON-CURRENT LIABILITIES
1,690,011
21,021
127,569
1,838,601
2,130,296
19,838
129,687
2,279,821
Trade payables
Other payables
Tax liabilities
Other current liabilities
Provisions for risks and charges
Derivative instruments measured at fair value
Loans - due within one year
Short-term debts to banks and other lenders
TOTAL CURRENT LIABILITIES
TOTAL SHAREHOLDERS’ EQUITY AND LIABILITIES
321,158
336,035
93,197
3,026
22,103
3,669
597,145
22,740
1,399,073
5,368,303
345,183
257,244
80,572
8,479
19,152
4,862
313,341
23,849
1,052,682
5,252,275
Share capital
Share premium reserve
Treasury shares
Reserve for derivative instruments
Translation reserve
Other reserves
Profits carried forward
Net income
Interim dividend
Shareholders’ equity attributable to equity holders of
the Parent
Shareholders’ equity attributable to non-controlling
interests
TOTAL SHAREHOLDERS’ EQUITY
Pending completion of independent audit
10
RECORDATI GROUP
Summary of consolidated results prepared in accordance with International Financial Reporting Standards (IFRS) (€ thousands)
CASH FLOW STATEMENT
First half 2026
First half 2025
269,674
92,233
45,007
19,295
86,093
0
23,551
10,579
29,615
216,121
68,230
48,288
17,755
83,888
0
8,936
55,983
(2,747)
576,047
496,453
296
(84,447)
(22,121)
(106,272)
2,089
(47,239)
(104,664)
319,961
(65,749)
(74,573)
37,471
(102,851)
2,503
(48,045)
(75,888)
272,172
(20,803)
244
(57,962)
791
254
(77,476)
(15,417)
79
(27,657)
87
0
(42,908)
3
(158,773)
(5,890)
(917)
(143,181)
(43,952)
64,122
(288,588)
(46,103)
428,824
8,662
391,383
276,809
(343,771)
(5,660)
56,373
(137,620)
(81,423)
32,996
(202,296)
26,968
322,423
(7,841)
341,550
OPERATING ACTIVITIES
Net income
Income taxes
Net interest
Depreciation of property, plant and equipment
Amortization of intangible assets
Write-downs
Equity-settled share-based payment transactions
Other non-monetary components
Change in other assets and other liabilities
Cash flow generated/(used) by operating activities before change in
working capital
Change in:
- inventories
- trade receivables
- trade payables
Change in working capital
Interest received
Interest paid
Income taxes paid
Cash flow generated/(used) by operating activities
INVESTMENT ACTIVITIES
Investments in property, plant and equipment
Disposals of property, plant and equipment
Investments in intangible assets
Disposals of intangible assets
Disposal of other assets
Cash flow generated/(used) by investment activities
FINANCING ACTIVITIES
Opening of loans
Repayment of loans
Payment of lease liabilities
Change in short-term debts to banks and other lenders
Dividends paid
Purchase of treasury shares
Sale of treasury shares
Cash flow generated/(used) by financing activities
Change in cash and cash equivalents
Opening cash and cash equivalents
Currency translation effect
Closing cash and cash equivalents
Pending completion of independent audit
DECLARATION BY THE FINANCIAL REPORTING OFFICER
The Financial Reporting Officer, Niccolò Giovannini, declares, pursuant to paragraph 2 of Article 154-bis
of the Consolidated Law on Finance, that the accounting information contained in this press release
corresponds to the Company’s documentation, books and accounting records.
11